Lecture 3 Flashcards

(30 cards)

0
Q

Digitalis

A

Used to treat dropsy (congestive heart failure)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
1
Q

Ma huang

A

Heart stimulant and for nasal and chest congestion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Target identification

A

Identification of biological components that are potentially drugable

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Target validation

A

Determines whether interfering with the target is likely to have an impact on cancer growth

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Target to hit

A

Large numbers of chemical and biological agents are screened to identify molecules that hit the target

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Hit to lead

A

Hits are further tested to determine which bind the target with my specificity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Lead optimization

A

Refining the properties of the lead molecules to enhance potency and reduce side effects

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Preclinical testing

A

Test for effectiveness of optimize lead

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Clinical trials

A

Determines whether it improves patient outcomes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Phase 1

A

3 to 18 months

Evaluate safety, tolerability, PK and effects in healthy volunteers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Phase 2

A

1-3 years.

Assesses effectiveness, side effects and other safety features and forms a dosing strategy and several HUNDRED patients

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Phase 3

A

2-6 years

Establishes efficacy and adverse effects from long-term uses and THOUSANDS of patients

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Phase 4

A

Continuous

Monitoring of effects contraindications and interactions reported by MD and Pharm.D.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

IND

A

Investigational new drug application

Before phase 1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

NDA

A

New drug application

After phase 3 before phase 4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Lipitor

A

HMG CoA inhibitor

Cholesterol

16
Q

Plavix

A

Antiplatelet

Thrombosis

17
Q

Nexium

A

Proton pump inhibitor

Antiulcer

18
Q

Norvasc

A

Calcium channel blocker.

Hypertension

19
Q

What is out there and is there room for improvement?

A

Cure rather than alleviating symptoms the holy Grail.
Act on underlying pathophysiology. Greater efficacy.
New dosage form
Fewer side effects

20
Q

Ideal target

A

Disease modifying or proven function
Known 3-D structure
Easy assay allowing high throughput screening

21
Q

To be a target?

A

It has to be validated

22
Q

Gene knockout

A

Removal of the gene that encodes for the biomolecule of interest

23
Q

RNAi

A

Double-stranded RNA interfering with the expression of genes the sequences complementary to dsRNA

24
Small Molecule Probe
Assay each compound against a disease model into you get a hit
25
Animal models
Difficult, time-consuming, expensive
26
Computation docking
Known, homologue or theorized structure of a protein can be modeled and molecules designed and tested for their interaction that may cause a confirmational change in the protein
27
Proteomics
Provides a protein profile of the cell tissue or body fluid that can be used to compare
28
Phenotype
Genotype Natural variation Environment
29
Phenotypic screening
Link between genetic alteration and disease phenotype | IDs a cause rather than a consequence